Prognosis of the life of patients with chronic heart failure and atrial fibrilla-tion, depending on the control of hemodynamic parameters and tolerance to physical exertion in the background of basic therapy

Actuality. In the basic therapy of CHF, drugs that reduce the pulse is one of the leading places. Target values of heart rate with sinus rhythm are established. Tere is still no consensus as to which heart rate is ideal in patients with CHF on the background of the rhythm of atrial fbrillation (AF). Te study of the prognosis in patients with CHF and AF depending on the achieved heart rate is relevant.

Objective. To analyze the overall mortality and establish the stratifcation risks of death in patients with CHF and AF depending on the form of AF, functional class of CHF and the presence of tachycardia.

Material and methods. A prospective cohort study was conducted in a group of patients with CHF who were observed at the City Center for CHF treatment (n = 591) during the year. Of these, 47.4% of patients had CHF and AF (n = 280) and 52.6% of patients with CHF without AF (n = 311).

Results. In a year, a permanent AF registered among patients with CHF and AF in 55.4%, persistent – in 36.4%, and paroxysmal – in 8.2% of cases. In 12.2% of patients, the diagnosis of AF was frst diagnosed. According to functional class of CHF, LVEF, assessment of clinical assessment scale, the group with a permanent AF was signifcantly heavier than without AF. Te mortality of patients with tachycardia signifcantly increased as a function of the increase in CHF from I–II to III–IV class: from 3.6% to 14.9% in the group without AF (p=0.04), and in the group with paroxysmal and persistent AF from 6.7% to 25.9% (p = 0.043). Te presence of tachycardia increases the risk of death by 61%, and the transition to a heavier functional class is 4.9 times. With each increase in the clinical assessment scale exponent by 1 point, the mortality rate in the sample is increased by 16%.

Conclusion. Heart rate is not an independent predictor of death, but in combination with functional class III–IV CHF tachycardia signifcantly worsens the prognosis.

1. Mareev V. Yu., Ageev F. T., Arutyunov G. P., Koroteev A. V., Mareev Yu. V., Ovchinnikov A. G. et al. SEHF, RSC and RSMSIM national guidelines on CHF diagnostics and treatment (fourth revision) Approved at the SEHF Congress on December 7, 2012, at the SEHF Board of Directors meeting on March 31, 2013, and at the RSC Congress on September 25, 2013. Russian Heart Failure Journal. 2013;14 (7):379–472. [Russian]. DOI: 10.18087/rhf.2013.7.1860

2. Polyakov D.S., Fomin I.V., Valikulova F.Yu., Vaisberg A.R., Kraiem N., Badin Yu.V. et al. Te EPOCH-CHF epidemiological program: decompensated chronic heart failure in real-life clinical practice (EPOCH-D–CHF). Russian Heart Failure Journal. 2016;17 (5):299– 305. [Russian]. DOI: 10.18087/rhf.2016.5.2239

3. Mareev V. Yu., Fomin I. V., Ageev F. T., Begrambekova Yu. L., Vasyuk Yu.A., Garganeeva A.A. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientifc Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58 (S6):8–164. [Russian]. DOI: 10.18087/cardio.2475

4. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JGF et al. Efcacy of β blockers in patients with heart failure plus atrial fbrillation: an individual-patient data meta-analysis. Te Lancet. 2014;384(9961):2235–43. DOI: 10.1016/S0140-6736(14)61373-8

5. McMurray J, Køber L, Robertson M, Dargie H, Colucci W, LopezSendon J et al. Antiarrhythmic effect of carvedilol afer acute myocardial infarction. Journal of the American College of Cardiology. 2005;45 (4):525–30. DOI: 10.1016/j.jacc.2004.09.076

6. Pedersen OD, Bagger H, Køber L, Torp-Pedersen C. Trandolapril Reduces the Incidence of Atrial Fibrillation Afer Acute Myocardial Infarction in Patients with Lef Ventricular Dysfunction. Circulation. 1999;100(4):376–80. DOI: 10.1161/01.CIR.100.4.376

7. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP et al. Prevention of atrial fbrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. American Heart Journal. 2006;152(1):86–92. PMID: 16838426

8. Swedberg K, Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Shi H et al. Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure. Journal of the American College of Cardiology. 2012;59(18):1598–603. DOI: 10.1016/j.jacc.2011.11.063

9. McAlister FA. Meta-analysis: β-blocker dose, heart rate reduction, and death in patients with heart failure. Annals of Internal Medicine. 2009;150(11):784–94. DOI: 10.7326/0003-4819-150-11-200906020-00006

10. Böhm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, LopezSendon J et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology. 2013;102(1):11–22. DOI: 10.1007/s00392-012-0467-8

11. Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of Randomized Controlled Trials on the Effect of Magnitude of Heart Rate Reduction on Clinical Outcomes in Patients with Systolic Chronic Heart Failure Receiving Beta-Blockers. Te American Journal of Cardiology. 2008;101(6):865–9. DOI: 10.1016/j.amjcard.2007.11.023

12. Fiuzat M, Wojdyla D, Pina I, Adams K, Whellan D, O’Connor CM. Heart Rate or Beta-Blocker Dose? Association with Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction. JACC: Heart Failure. 2016;4(2):109–15. DOI: 10.1016/j.jchf.2015.09.002

13. Cullington D, Goode KM, Clark AL, Cleland JGF. Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target? European Journal of Heart Failure. 2012;14(7):737–47. DOI: 10.1093/eurjhf/hfs060

14. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fbrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893–962. DOI: 10.1093/eurheartj/ehw210

15. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128(16):e240-327. DOI: 10.1161/CIR.0b013e31829e8776

16. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Te Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129–200. DOI: 10.1093/eurheartj/ehw128

17. O’Meara E, Solomon S, McMurray JJ, Pfeffer M, Yusuf S, Michelson E et al. Effect of candesartan on New York Heart Association functional classResults of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal. 2004;25(21):1920–6. DOI: 10.1016/j.ehj.2004.07.025

18. Koziolova N. A., Nikonova Yu. N., Shilova Ya. E., Agafonov A. V., Polianskaya E. A. Description of chronic heart failure against the background of permanent atrial fbrillation. Russian Heart Failure Journal. 2013;14 (1):14–21. [Russian]. DOI: 10.18087/rhf.2013.1.1806

19. Tihalolipavan S, Morin DP. Atrial Fibrillation and Heart Failure: Update 2015. Progress in Cardiovascular Diseases. 2015;58(2):126– 35. DOI: 10.1016/j.pcad.2015.07.004

20. Fiuzat M, Wojdyla D, Kitzman D, Fleg J, Keteyian SJ, Kraus WE et al. Relationship of Beta-Blocker Dose with Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction. Journal of the American College of Cardiology. 2012;60(3):208–15. DOI: 10.1016/j.jacc.2012.03.023

21. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH et al. Dosing of Beta-Blocker Terapy Before, During, and Afer Hospitalization for Heart Failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). Te American Journal of Cardiology. 2008;102(11):1524–9. DOI: 10.1016/j.amjcard.2008.07.045

22. Dierckx R, Cleland JGF, Parsons S, Putzu P, Pellicori P, Dicken B et al. Prescribing Paterns to Optimize Heart Rate: analysis of 1,000 consecutive outpatient appointments to a single heart failure clinic over a 6-month period. JACC: Heart Failure. 2015;3(3):224–30. DOI: 10.1016/j.jchf.2014.11.003

23. Wikstrand J, Hjalmarson Å ke, Waagstein F, Fagerberg B jörn, Goldstein S, Kjekshus J et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF) . Journal of the American College of Cardiology. 2002;40(3):491–8. DOI: 10.1016/S0735-1097(02)01970-8

24. Vinogradova N. G., Fomin I. V., Polyakov D. S., Zhirkova M. M., Tyurin A. A., Krylova A. N. et al. Effectiveness of control over hemodynamic indexes and prognosis for patients with CHF and atrial fbrillation in real-life clinical practice. Kardiologiia. 2018,58(S8):43–53. [Russian]. DOI: 10.18087/cardio.2440

25. Laskey WK, Alomari I, Cox M, Schulte PJ, Zhao X, Hernandez AF et al. Heart Rate at Hospital Discharge in Patients with Heart Failure Is Associated With Mortality and Rehospitalization. Journal of the American Heart Association. 2015;4(4):e001626–e001626. DOI: 10.1161/JAHA.114.001626

26. Li S-J, Sartipy U, Lund LH, Dahlström U, Adiels M, Petzold M et al. Prognostic Signifcance of Resting Heart Rate and Use of β-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients with Heart Failure and Reduced Ejection FractionCLINICAL PERSPECTIVE: Findings From the Swedish Heart Failure Registry. Circulation: Heart Failure. 2015;8(5):871–9. DOI: 10.1161/CIRCHEARTFAILURE.115.002285

27. Simpson J, Castagno D, Doughty RN, Poppe KK, Earle N, Squire I et al. Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fbrillation? Results from the MAGGIC meta-analysis. European Journal of Heart Failure. 2015;17(11):1182–91. DOI: 10.1002/ejhf.346

28. Rienstra M, Damman K, Mulder BA, Van Gelder IC, McMurray JJV, Van Veldhuisen DJ. Beta-Blockers and Outcome in Heart Failure and Atrial Fibrillation. JACC: Heart Failure. 2013;1(1):21–8. DOI: 10.1016/j.jchf.2012.09.002

29. Cullington D, Goode KM, Zhang J, Cleland JGF, Clark AL. Is heart rate important for patients with heart failure in atrial fbrillation? JACC. Heart failure. 2014;2(3):213–20. DOI: 10.1016/j.jchf.2014.01.005

30. Mareev Y, Cleland JGF. Should β-blockers be used in patients with heart failure and atrial fbrillation? Clinical Terapeutics. 2015;37 (10):2215–24. DOI: 10.1016/j.clinthera.2015.08.017